Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Ligand exercises final option to buy down Ontak royalties

April 12, 2005

Siplizumab under investigation for CD2-positive lymphoproliferative disorders

April 8, 2005

Argos' personalized melanoma vaccine studied in Germany

April 8, 2005

Adoptive cell transfer demonstrates activity in metastatic melanoma patients

April 7, 2005

ImmunoGen submits IND for huC242-DM4

April 4, 2005

Orphan medicinal product status for TGN-1412 in Europe

April 4, 2005

Promising effects reported for Proxinium in head and neck cancer

April 1, 2005

Enrollment under way in phase II study of AVR-118 in advanced cancer patients

April 1, 2005

IND accepted for MORAb-003

March 31, 2005

Enrollment completed in phase I/II CLL study of HuMax-CD20

March 31, 2005

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 27, 2026.
Brain-penetrant NLRP3 inhibitor shows promise in Parkinson’s
BioWorld Science
Researchers from Changchun Genescience Pharmaceuticals Co. Ltd. described the discovery and preclinical profile of an NLRP3 inhibitor with favorable brain...
4D Nucleome opens new wave of gene regulation research, discovery
BioWorld
After a decade of research, the NIH 4D Nucleome program on July 23 delivered a wealth of new insights into how spatial changes in chromatin structure and DNA...
Daybu readthrough in EU? Zevra’s NPC bid flounders
BioWorld
Zevra Therapeutics Inc. will try to follow in the footsteps of Acadia Pharmaceuticals Inc. with Rett syndrome drug Daybu (trofinetide) by asking the EMA’s...
Transcripta Bio raises funding to advance neuro pipeline
BioWorld Science
Transcripta Bio Inc. has raised $24 million since its series A to fund IND-enabling studies across its portfolio and support clinical preparation in its autism...